Ophthalmic Artery Chemosurgery for Less Advanced Intraocular Retinoblastoma: Five Year Review

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 May 1

PMID 22545080

Citations 22

Authors

David H Abramson

Brian P Marr

Scott E Brodie

Ira Dunkel

Sotiria Palioura

Y Pierre Gobin

Affiliations

Soon will be listed here.

Abstract

Background: Ophthalmic artery chemosurgery (OAC) for retinoblastoma was introduced by us 5 years ago for advanced intraocular retinoblastoma. Because the success was higher than with existing alternatives and systemic side effects limited we have now treated less advanced intraocular retinoblastoma (Reese-Ellsworth (RE) I-III and International Classification Retinoblastoma (ICRB) B and C).

Methodology/principal Findings: Retrospective review of 5 year experience in eyes with Reese Ellsworth (Table 1) I (7 eyes), II (6 eyes) or III (6 eyes) and/or International Classification (Table 2) B (19 eyes) and C (11 eyes) treated with OAC (melphalan with or without topotecan) introduced directly into the ophthalmic artery. Patient survival was 100%. Ocular event-free survival was 100% for Reese-Ellsworth Groups I, II and III (and 96% for ICRB B and C) at a median of 16 months follow-up. One ICRB Group C (Reese-Ellsworth Vb) eye could not be treated on the second attempt for technical reasons and was therefore enucleated. No patient required a port and only one patient required transfusion of blood products. The electroretinogram (ERG) was unchanged or improved in 14/19 eyes.

Conclusions/significance: Ophthalmic artery chemosurgery for retinoblastoma that was Reese-Ellsworth I, II and III (or International Classification B or C) was associated with high success (100% of treatable eyes were retained) and limited toxicity with results that equal or exceed conventional therapy with less toxicity.

Citing Articles

Ocular survival after intra-arterial chemotherapy for retinoblastoma improves with accrual of experience and programmatic evolution.

Marasligiller S, Williams B, Vadivelu S, Correa Z, Abruzzo T, Di Nicola M Pediatr Blood Cancer. 2022; 70(2):e30071.

PMID: 36349521 PMC: 9790034. DOI: 10.1002/pbc.30071.

Treatment of Retinoblastoma: What Is the Latest and What Is the Future.

Schaiquevich P, Francis J, Cancela M, Montero Carcaboso A, Chantada G, Abramson D Front Oncol. 2022; 12:822330.

PMID: 35433448 PMC: 9010858. DOI: 10.3389/fonc.2022.822330.

Current Indications of Secondary Enucleation in Retinoblastoma Management: A Position Paper on Behalf of the European Retinoblastoma Group (EURbG).

Stathopoulos C, Lumbroso-Le Rouic L, Moll A, Parulekar M, Maeder P, Doz F Cancers (Basel). 2021; 13(14).

PMID: 34298608 PMC: 8303810. DOI: 10.3390/cancers13143392.

Intravenous Chemotherapy for Retinoblastoma in the Era of Intravitreal Chemotherapy: A Systematic Review.

Raval V, Bowen R, Soto H, Singh A Ocul Oncol Pathol. 2021; 7(2):142-148.

PMID: 33981697 PMC: 8077434. DOI: 10.1159/000510506.

Retinoblastoma management in 13q deletion syndrome patients using super-selective chemotherapies and other cancer-directed interventions.

Cobbs L, Francis J, Dunkel I, Gobin Y, Brodie S, Abramson D Pediatr Blood Cancer. 2020; 68(5):e28845.

PMID: 33355996 PMC: 9316827. DOI: 10.1002/pbc.28845.

References

Kim J, Yu Y, Khwarg S, Choi H, Shin H, Ahn H . Clinical result of prolonged primary chemotherapy in retinoblastoma patients. Korean J Ophthalmol. 2003; 17(1):35-43. DOI: 10.3341/kjo.2003.17.1.35. View

Hernandez J, BRADY L, Shields J, Shields C, DePotter P, Karlsson U . External beam radiation for retinoblastoma: results, patterns of failure, and a proposal for treatment guidelines. Int J Radiat Oncol Biol Phys. 1996; 35(1):125-32. DOI: 10.1016/s0360-3016(96)85020-6. View

Vajzovic L, Murray T, Aziz-Sultan M, Schefler A, Wolfe S, Hess D . Supraselective intra-arterial chemotherapy: evaluation of treatment-related complications in advanced retinoblastoma. Clin Ophthalmol. 2011; 5:171-6. PMC: 3045066. DOI: 10.2147/OPTH.S12665. View

Munier F, Beck-Popovic M, Balmer A, Gaillard M, Bovey E, Binaghi S . Occurrence of sectoral choroidal occlusive vasculopathy and retinal arteriolar embolization after superselective ophthalmic artery chemotherapy for advanced intraocular retinoblastoma. Retina. 2011; 31(3):566-73. DOI: 10.1097/IAE.0b013e318203c101. View

Toral-Martinnon R, Collado-Corona M, Mora-Magana I, Leal-Leal C, Gutierrez-Castrellon P, Leo S . [Evaluation of cisplatin ototoxicity by the audiometric curve in retinoblastoma]. Cir Cir. 2006; 74(2):79-82. View

Egbert P, Donaldson S, Moazed K, Rosenthal A . Visual results and ocular complications following radiotherapy for retinoblastoma. Arch Ophthalmol. 1978; 96(10):1826-30. DOI: 10.1001/archopht.1978.03910060338008. View

Rizzuti A, Dunkel I, Abramson D . The adverse events of chemotherapy for retinoblastoma: what are they? Do we know?. Arch Ophthalmol. 2008; 126(6):862-5. DOI: 10.1001/archopht.126.6.862. View

Brodie S, Gobin Y, Dunkel I, Kim J, Abramson D . Persistence of retinal function after selective ophthalmic artery chemotherapy infusion for retinoblastoma. Doc Ophthalmol. 2009; 119(1):13-22. DOI: 10.1007/s10633-008-9164-3. View

Kim J, Abramson D, Dunkel I . Current management strategies for intraocular retinoblastoma. Drugs. 2007; 67(15):2173-85. DOI: 10.2165/00003495-200767150-00005. View

10.

Gobin Y, Dunkel I, Marr B, Brodie S, Abramson D . Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol. 2011; 129(6):732-7. DOI: 10.1001/archophthalmol.2011.5. View

11.

Cassady J, Sagerman R, Tretter P, Ellsworth R . Radiation therapy in retinoblastoma. An analysis of 230 cases. Radiology. 1969; 93(2):405-9. DOI: 10.1148/93.2.405. View

12.

Gombos D, Hungerford J, Abramson D, Kingston J, Chantada G, Dunkel I . Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor?. Ophthalmology. 2007; 114(7):1378-83. DOI: 10.1016/j.ophtha.2007.03.074. View

13.

Bhagat S, Bass J, White S, Qaddoumi I, Wilson M, Wu J . Monitoring carboplatin ototoxicity with distortion-product otoacoustic emissions in children with retinoblastoma. Int J Pediatr Otorhinolaryngol. 2010; 74(10):1156-63. PMC: 4787621. DOI: 10.1016/j.ijporl.2010.07.004. View

14.

Friedman D, Himelstein B, Shields C, Shields J, Needle M, Miller D . Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol. 2000; 18(1):12-7. DOI: 10.1200/JCO.2000.18.1.12. View

15.

Oktay K, Rodriguez-Wallberg K, Schover L . Preservation of fertility in patients with cancer. N Engl J Med. 2009; 360(25):2681. View

16.

Suzuki S, Yamane T, Mohri M, Kaneko A . Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis. Ophthalmology. 2011; 118(10):2081-7. DOI: 10.1016/j.ophtha.2011.03.013. View

17.

Abramson D, Dunkel I, Brodie S, Kim J, Gobin Y . A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology. 2008; 115(8):1398-404, 1404.e1. DOI: 10.1016/j.ophtha.2007.12.014. View

18.

Liberman P, Schultz C, Goffi-Gomez M, Antoneli C, Motoro Chojniak M, Novaes P . Evaluation of ototoxicity in children treated for retinoblastoma: preliminary results of a systematic audiological evaluation. Clin Transl Oncol. 2011; 13(5):348-52. DOI: 10.1007/s12094-011-0665-2. View

19.

Abramson D, Schefler A . Transpupillary thermotherapy as initial treatment for small intraocular retinoblastoma: technique and predictors of success. Ophthalmology. 2004; 111(5):984-91. DOI: 10.1016/j.ophtha.2003.08.035. View

20.

Gunduz K, Gunalp I, Yalcindag N, Unal E, Tacyildiz N, Erden E . Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation. Ophthalmology. 2004; 111(10):1917-24. DOI: 10.1016/j.ophtha.2004.04.016. View